Basket Study at Providence Medical Group

Providence Medical Group is currently enrolling patients for the following basket studies:

A Phase 1/2 Study of Galinpepimut-S in Combination with Pembrolizumab (MK-3475) in Patients with Selected Advanced Cancers (SELLAS)

Treatment agent: Galinpepimut-S (WT1 immunotx) + pembroPI: Jarrod Holmes, MD
Study Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: clinicaltrials.gov NCT No: NCT03761914

A Phase 1/2 Study of Galinpepimut-S in Combination with Pembrolizumab (MK-3475) in Patients with Selected Advanced Cancers (SELLAS)

Treatment agent: Galinpepimut-S (WT1 immunotx) + pembro
PI: Jarrod Holmes, MD
Study Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: clinicaltrials.gov NCT No: NCT03761914

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Another Anti-cancer Therapy for Treatment of Recurrent (Non-small Cell) Lung Cancer. (GCT1046-04)

Treatment: ABBV-927 with ABBV-368, budigalimab (ABBV-181), and/or chemotherapy
PI: Ian Anderson, MD
Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT05117242?term=NCT05117242&draw=2&rank=1
Sponsor: Genmab

Study of Magrolimab in Participants with Solid Tumors

Treatment: Mabrolimab + Docetaxel
PI: Ian Anderson, MD
Coordinator: Charity Behrend // charity.behrend@providence.org // (707) 521-3830 ext. 1181
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04827576?term=Gilead+GS-US-548-5918&draw=2&rank=1
Sponsor: Gilead Sciences, Inc.